The majority of patients with psoriatic arthritis are not eligible for randomised clinical trials.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsRunarsdottir, Eydis E
Gunnarsdottir, Anna I
Love, Thorvardur J
Gunnarsson, Petur S
MetadataShow full item record
CitationThe majority of patients with psoriatic arthritis are not eligible for randomised clinical trials. 2018, 36(6):1068-1073 Clin Exp Rheumatol
AbstractTo identify the proportion of patients with psoriatic arthritis (PsA) who would meet inclusion criteria of the randomised clinical trials that were performed leading up to registration of the tumour necrosis factor inhibitors (TNFi). Data from 329 patients with PsA were obtained from an Icelandic database, ICEBIO, medical records at the University Hospital of Iceland, and the private out-patient clinic Laeknasetrid Ltd. The patients were classified according to whether they met the inclusion criteria of the clinical trials that were performed ahead of the registration of each respective TNFi. The reasons for exclusion were also explored. 34% of the patients with complete data available met the inclusion criteria. Clinical data in respect to exclusion and inclusion criteria were incomplete for 13% of the cases. The proportion of patients who met the inclusion criteria was highest among those who received adalimumab and etanercept (53%). Patients who received in iximab had the lowest inclusion rate (23%). The main reason why patients did not meet the inclusion criteria was too few swollen and/or tender joints, or in 45% of excluded cases. Our results demonstrate that two thirds of patients with PsA in Iceland who are treated with TNFi would not have qualified for the randomised clinical trials performed leading up to the registration of the medications. Further studies with regards to whether outcomes are different between those who met the inclusion criteria and those who did not remain to be performed.
- Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible.
- Authors: Palsson O, Love TJ, Gunnarsdottir AI, Gunnarsson PS, Runarsdottir EE, Krogh NS, Gudbjornsson B
- Issue date: 2019
- The influence of obesity on response to tumour necrosis factor-α inhibitors in psoriatic arthritis: results from the DANBIO and ICEBIO registries.
- Authors: Højgaard P, Glintborg B, Kristensen LE, Gudbjornsson B, Love TJ, Dreyer L
- Issue date: 2016 Dec
- Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
- Authors: Favalli EG, Pontikaki I, Becciolini A, Biggioggero M, Ughi N, Romano M, Crotti C, Gattinara M, Gerloni V, Marchesoni A, Meroni PL
- Issue date: 2017 Aug
- Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.
- Authors: Saad AA, Symmons DP, Noyce PR, Ashcroft DM
- Issue date: 2008 May
- Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
- Authors: Atzeni F, Costa L, Caso F, Scarpa R, Sarzi-Puttini P
- Issue date: 2015 Nov